Skyrizi and Hospitalisation - a phase IV clinical study of FDA data

Summary:

Hospitalisation is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Humira, and have Psoriasis.

The phase IV clinical study analyzes which people have Hospitalisation when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Hospitalisation?

Hospitalisation is found to be associated with 1,717 drugs and 1,133 conditions by eHealthMe. Check the latest studies of Hospitalisation.

On Jul, 29, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 326 people (0.72%) have Hospitalisation.

Among these 326 people:

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Hospitalisation?

- Check whether Hospitalisation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Hospitalisation treatments and more:

Hospitalisation (143,651 reports)

How severe was Hospitalisation and when was it recovered:

Hospitalisation in Skyrizi

Expand to all the drugs that have ingredients of risankizumab-rzaa:

Hospitalisation and drugs with ingredients of risankizumab-rzaa

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hospitalisation:

Hospitalisation (1,717 drugs)

Browse all the conditions that are associated with Hospitalisation:

Hospitalisation (1,133 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.